Novateor Research Laboratories
NOVATEORRESEARCHLABORATORIESLTD NSE
Novateor Research Laboratories
Consumer GoodsNSE: NOVATEORRESEARCHLABORATORIESLTD BSE: 542771 Personal Care
Key Fundamentals
SMEPersonal CareConsumer GoodsMarket Cap
₹21.20 Cr
Volatility
Low Risk
P/E Ratio
206.5
EBITDA
₹-0.10 Cr
Return on Equity
0.78%
Debt to Equity
0.09
Book Value
₹18.51
EPS
₹0.06
52W High
₹35.1
52W Low
₹20.08
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.72% over last 3 years.
- Company has high debtors of 269 days.
- Promoter holding has decreased over last 3 years: -10.1%
Growth Rate
Revenue Growth
16.06% lower than
3Y
Net Income Growth
10% lower than
3Y
Cash Flow Change
-5.1% higher than
3Y
ROE
136% higher than
3Y
ROCE
107% lower than
3Y
EBITDA Margin (Avg.)
-122% higher than
3Y
Quarterly Results
| Particulars | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.07 | 0.12 | 0.28 | 0.46 | 0.82 | 0.44 | 0.36 | 0.85 | 0.79 | 1.98 | 2.47 | 1.36 |
| Expenses | 0.16 | 0.36 | 0.35 | 0.57 | 1.01 | 0.58 | 0.53 | 1 | 0.9 | 2 | 2.59 | 1.35 |
| Operating Profit | -0.09 | -0.24 | -0.07 | -0.11 | -0.19 | -0.14 | -0.17 | -0.15 | -0.11 | -0.02 | -0.12 | 0.01 |
| OPM % | -128.57% | -200% | -25% | -23.91% | -23.17% | -31.82% | -47.22% | -17.65% | -13.92% | -1.01% | -4.86% | 0.74% |
| Other Income | 0 | 0.44 | -0.21 | 0.22 | 0.24 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 | 0.25 | 0.24 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.02 | 0.01 | 0.02 | 0.05 | 0.05 | 0.04 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.1 | 0.09 | 0.09 |
| PBT | -0.14 | 0.15 | -0.33 | 0.07 | 0.01 | 0.04 | 0.01 | 0.04 | 0.05 | 0.07 | -0.01 | 0.12 |
| Tax % | 0% | 0% | 0% | -42.86% | 0% | 0% | 0% | 0% | 20% | 28.57% | 100% | 8.33% |
| Net Profit | -0.13 | 0.15 | -0.33 | 0.1 | 0.01 | 0.03 | 0.01 | 0.04 | 0.03 | 0.05 | -0.02 | 0.12 |
| EPS in Rs | -0.27 | 0.31 | -0.68 | 0.21 | 0.02 | 0.06 | 0.02 | 0.08 | 0.06 | 0.1 | -0.03 | 0.2 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.02 | 0.1 | 0.14 | 0.09 | 0.41 | 0.39 | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 |
| Expenses | 0.02 | 0.11 | 0.08 | 0.04 | 0.13 | 0.53 | 0.52 | 0.92 | 1.6 | 1.54 | 2.92 | 3.93 |
| Operating Profit | 0 | -0.01 | 0.06 | 0.05 | 0.28 | -0.14 | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.1 |
| OPM % | 0% | -10% | 42.86% | 55.56% | 68.29% | -35.9% | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -2.61% |
| Other Income | 0 | 0.01 | 0.02 | 0.03 | 0.11 | 0.27 | 0.44 | 0.01 | 0.49 | 0.49 | 0.48 | 0.49 |
| Interest | 0 | 0 | 0.01 | 0.01 | 0 | 0.01 | 0 | 0 | 0.02 | 0.03 | 0.07 | 0.09 |
| Depreciation | 0 | 0 | 0.07 | 0.07 | 0.1 | 0.1 | 0.1 | 0.09 | 0.09 | 0.08 | 0.16 | 0.19 |
| PBT | 0 | 0 | 0 | 0 | 0.29 | 0.02 | 0.01 | -0.26 | 0.04 | 0.05 | 0.11 | 0.11 |
| Tax % | — | — | — | — | 24.14% | 150% | 0% | -11.54% | 0% | 40% | 27.27% | 18.18% |
| Net Profit | 0 | 0 | 0 | 0 | 0.22 | -0.01 | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.1 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0.74 | -0.02 | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
| Div. Payout % | — | — | — | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 0.05 | 2.96 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 6.05 |
| Reserves | 0.88 | 0.88 | 0.88 | 0.88 | 1.11 | 3.73 | 3.74 | 3.01 | 3.04 | 3.93 | 5.71 | 5.45 |
| Borrowings | 0.75 | 0.76 | 0.87 | 0.82 | 0.01 | 0 | 0.24 | 0.24 | 0.84 | 1.11 | 0.91 | 1.02 |
| Other Liabilities | 0.11 | 0.15 | 0.1 | 0.09 | 0.24 | 0.23 | 0.17 | 0.06 | 0.24 | 0.59 | 1.16 | 1.74 |
| Total Liabilities | 1.79 | 1.84 | 1.9 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.26 |
| Fixed Assets | 1.59 | 1.64 | 1.66 | 1.59 | 3.55 | 3.45 | 3.36 | 1.94 | 1.78 | 2.43 | 3.41 | 3.24 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.43 | 0.44 | 0 | 0 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 0.19 | 0.19 | 0.23 | 0.24 | 0.76 | 5.33 | 5.61 | 6.19 | 6.73 | 7.58 | 9.19 | 11.01 |
| Total Assets | 1.79 | 1.84 | 1.9 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.26 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 0.01 | 0.05 | -0.07 | -3.42 | -0.27 | -0.97 | -0.97 | -0.98 | -1.03 | -0.18 |
| Investing | 0 | 0 | -0.01 | 0 | -1.96 | -0.1 | -0.09 | 0.91 | 0.13 | -0.25 | -0.22 | -0.5 |
| Financing | 0 | 0 | 0 | -0.03 | 2.03 | 4.18 | 0.32 | -0.13 | 0.58 | 1.1 | 1.43 | 0.89 |
| Net Cash Flow | 0 | 0 | -0.01 | 0.02 | 0 | 0.67 | -0.04 | -0.18 | -0.26 | -0.13 | 0.18 | 0.2 |
| Free Cash Flow | 0 | 0 | 0 | 0.05 | -2.03 | -3.52 | -0.36 | -0.06 | -1.33 | -1.72 | -1.73 | -0.2 |
| CFO/OP | — | 0 | 17 | 100 | 0 | 2,443 | 82 | 539 | 285 | 297 | 736 | 180 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 219 | 183 | 243 | 134 | 234 | 384 | 212 | 203 | 338 | 272 | 269 |
| Inventory Days | 4,380 | 438 | 1,460 | 2,738 | 6,448 | 701 | 852 | 344 | 215 | 269 | 151 | 152 |
| Days Payable | 1,460 | 292 | 730 | 1,095 | 1,460 | 14.6 | 104 | 20.66 | 61.47 | 207 | 177 | 209 |
| Cash Conversion Cycle | 3,285 | 365 | 913 | 1,886 | 5,122 | 920 | 1,132 | 536 | 356 | 399 | 246 | 212 |
| Working Capital Days | 1,278 | 110 | 287 | 527 | 463 | 4,118 | 9,067 | 2,747 | 1,605 | 1,879 | 951 | 771 |
| ROCE % | 0% | 0% | 0.57% | 0.56% | 9.95% | 0.47% | 0.12% | 2.49% | 0.71% | 0.86% | 1.69% | 1.67% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Novateor Research Laboratories insights
53 extracted metrics + investor summaries across FY15–FY26.
Documents
1
Launch Of New Product- Smiloshine Herbafresh Toothpaste
30 Apr - Launched SmiloShine Herbafresh Toothpaste on 30 Apr 2026 in 6g and 100g variants for domestic and international markets. 30 Apr - Launched SmiloShine Herbafresh Toothpaste on 30 Apr 2026 in 6g and 100g variants for domestic and international markets.
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Novateor says it is not a Large Corporate under SEBI; FY2025-26 incremental borrowing was 0.7 Cr. 30 Apr - Novateor says it is not a Large Corporate under SEBI; FY2025-26 incremental borrowing was 0.7 Cr.
3
Launch Of New Product- Smiloshine Herbafresh Toothpaste
30 Apr - Launched SmiloShine Herbafresh Toothpaste on 30 Apr 2026 in 6g and 100g variants for domestic and international markets. 30 Apr - Launched SmiloShine Herbafresh Toothpaste on 30 Apr 2026 in 6g and 100g variants for domestic and international markets.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Novateor says it is not a Large Corporate under SEBI; FY2025-26 incremental borrowing was 0.7 Cr. 30 Apr - Novateor says it is not a Large Corporate under SEBI; FY2025-26 incremental borrowing was 0.7 Cr.
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - RTA issued Regulation 74(5) certificate for quarter ended 31 March 2026. 7 Apr - RTA issued Regulation 74(5) certificate for quarter ended 31 March 2026.
Frequently Asked Questions about Novateor Research Laboratories
What does Novateor Research Laboratories Ltd do?
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products.[1]
Where is Novateor Research Laboratories Ltd (542771) listed?
Novateor Research Laboratories Ltd trades as NOVATEORRESEARCHLABORATORIESLTD on the NSE and under code 542771 on the BSE.
Which sector does Novateor Research Laboratories Ltd belong to?
Novateor Research Laboratories Ltd is classified under the Consumer Goods sector, in the Personal Care industry.
What is the market capitalisation of Novateor Research Laboratories Ltd?
Novateor Research Laboratories Ltd has a market capitalisation of ₹21.2 Cr, which places it in the Small Cap band.
What is the PE ratio of Novateor Research Laboratories Ltd?
Novateor Research Laboratories Ltd trades at a PE ratio of 206.50, on earnings per share of ₹0.06, against a book value of ₹18.51 per share.
What is the 52-week high and low of Novateor Research Laboratories Ltd?
Over the last 52 weeks Novateor Research Laboratories Ltd has traded between ₹20.08 and ₹35.1.
What is the Return on Equity (ROE) of Novateor Research Laboratories Ltd?
Novateor Research Laboratories Ltd reported a return on equity of 0.78%. Its debt-to-equity ratio is 0.09.
Company Information
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/542771.md for Novateor Research Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.